Pacer Advisors Inc. Has $7.13 Million Holdings in Danaher Corporation (NYSE:DHR)

Key Points

• Pacer Advisors Inc. reduced its stake in Danaher Corporation by 31.7%, selling 16,181 shares during the 1st quarter, and now holds 34,784 shares valued at $7,131,000.
• Analysts have recently set mixed price targets for Danaher, with HSBC lowering its target from $270 to $240, while Scotiabank upgraded it to $275, resulting in an average price target of $247.61.
• Danaher recently reported quarterly earnings of $1.80 per share, surpassing estimates, along with revenues of $5.94 billion, reflecting a 3.4% increase compared to the same quarter last year.

Pacer Advisors Inc. decreased its position in Danaher Corporation (NYSE:DHR - Free Report) by 31.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 34,784 shares of the conglomerate's stock after selling 16,181 shares during the quarter. Pacer Advisors Inc.'s holdings in Danaher were worth $7,131,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in DHR. GHP Investment Advisors Inc. lifted its holdings in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in Danaher during the 4th quarter worth $27,000. Sierra Ocean LLC boosted its position in Danaher by 116.9% during the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after acquiring an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher during the 1st quarter worth $31,000. Finally, Hurley Capital LLC acquired a new position in Danaher during the 4th quarter worth $34,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Up 1.9%

Shares of DHR traded up $3.89 during trading hours on Tuesday, hitting $206.83. 4,973,284 shares of the company were exchanged, compared to its average volume of 4,283,577. The company has a market cap of $148.10 billion, a PE ratio of 44.01, a PEG ratio of 2.86 and a beta of 0.77. The firm's 50 day moving average is $196.51 and its 200-day moving average is $203.22. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. During the same quarter in the prior year, the company posted $1.72 EPS. The firm's revenue was up 3.4% on a year-over-year basis. On average, equities research analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, July 25th. Investors of record on Friday, June 27th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 0.62%. Danaher's payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. JPMorgan Chase & Co. cut their price objective on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. UBS Group cut their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Guggenheim reaffirmed a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Finally, Wells Fargo & Company cut their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $247.61.

Insider Activity at Danaher

In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the transaction, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This represents a 51.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman directly owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. This trade represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.